SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
RANCHO CORDOVA, Calif., March 31, 2016 -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will present a poster titled “Volume Reduction and RBC Depletion of Apheresis Products for Transplant” at the 42nd Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT) to be held in Valencia, Spain on April 3 – 6, 2016.
The poster describes progress in the development of new transplant protocols based on Cesca Therapeutics’ proprietary AutoXpress® platform for cellular processing. The work is based on a project that addresses the need for volume reduction and severe red blood cell depletion during the preparation of adult stem cells for bone marrow transplantation. The Company’s AutoXpress® platform, which includes an automated ‘smart’ processing device, a functionally closed disposable bag set and software, is fully compliant with the Good Manufacturing Processes employed in cell manufacturing facilities that prepare cellular therapeutics.
The EBMT conference attracts more than 4,000 participants annually, including international experts, scientists, physicians, nurse practitioners, clinical researchers, technicians, patients and laboratory personnel, from all over the world. The scientific program includes symposia, educational sessions and workshops covering key issues relating to bone marrow and stem cell transplantation. The conference also offers medical technology and pharmaceutical companies an opportunity to display new technologies and products that lead the advancement of the practice of cellular therapy.
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of autologous cell-based therapies for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:
The SurgWerks™ Platform - proprietary, indication-specific stem cell therapy kits and associated devices, for use at the point-of-care in treating vascular and orthopedic diseases.
The CellWerks™ Platform - a proprietary stem cell laboratory system for processing target cells used in the treatments of oncological and hematological disorders.
The AutoXpress® Platform (AXP®) - a proprietary automated device with a companion sterile disposable bag set for concentrating hematopoietic stem cells from cord blood.
The MarrowXpress® Platform (MXP®) - a derivative product of the AXP and its accompanying disposable bag set for the isolation and concentration of stem cells from bone marrow.
The BioArchive® System, an automated system used by cord blood banks for the cryopreservation and storage of cord blood stem cell specimens for future use in approved regenerative medicine procedures.
Forward Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Contact: Cesca Therapeutics Inc. http://www.cescatherapeutics.com Investor Contact: Lee Roth / Tram Bui 646-536-7012 / 7035 [email protected] / [email protected]
